Approval Background

Refilgrastim is a long-acting G-CSF (granulocyte-colony stimulating factor) inducer, used to prevent chemotherapy-induced neutropenia. The EMA reviewed clinical trial results and granted final approval on July 25, 2013. This approval reflects expectations that it will improve treatment continuity and reduce hospitalization periods for patients.

Clinical Evidence

According to the EPAR report, refilgrastim demonstrates similar white blood cell recovery efficacy to existing pegfilgrastim while extending the dosing interval. Clinical data from randomized controlled trials have demonstrated a favorable safety profile. These results suggest improved patient compliance and the potential for reduced healthcare costs.

Market and Competitive Positioning

In the European market, long-acting G-CSFs compete with products such as pegfilgrastim. Refilgrastim differentiates itself by offering greater dosing interval convenience. However, the brand recognition of existing products and insurance coverage policies may act as barriers to entry.

Impact on Patients and Healthcare Professionals

By providing sustained efficacy with a single injection, refilgrastim reduces the burden of hospital visits for patients. Healthcare professionals benefit from simplified dosing schedules, increasing work efficiency. In the long term, it is expected to contribute to improved quality of life for patients undergoing chemotherapy.